MX2023013619A - Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2. - Google Patents

Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2.

Info

Publication number
MX2023013619A
MX2023013619A MX2023013619A MX2023013619A MX2023013619A MX 2023013619 A MX2023013619 A MX 2023013619A MX 2023013619 A MX2023013619 A MX 2023013619A MX 2023013619 A MX2023013619 A MX 2023013619A MX 2023013619 A MX2023013619 A MX 2023013619A
Authority
MX
Mexico
Prior art keywords
her2
breast cancer
treatment
drug conjugate
expressing breast
Prior art date
Application number
MX2023013619A
Other languages
English (en)
Inventor
Jianmin Fang
Xiaohong Su
Original Assignee
Remegen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Co Ltd filed Critical Remegen Co Ltd
Publication of MX2023013619A publication Critical patent/MX2023013619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporciona un método para tratar a un paciente con cáncer de mama con expresión baja del receptor 2 del factor de crecimiento epidérmico humano (HER2).
MX2023013619A 2021-05-24 2022-05-18 Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2. MX2023013619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110565350 2021-05-24
PCT/CN2022/093632 WO2022247708A1 (en) 2021-05-24 2022-05-18 Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer

Publications (1)

Publication Number Publication Date
MX2023013619A true MX2023013619A (es) 2023-11-30

Family

ID=84228424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013619A MX2023013619A (es) 2021-05-24 2022-05-18 Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2.

Country Status (11)

Country Link
US (1) US20240207424A1 (es)
EP (1) EP4346908A1 (es)
JP (1) JP2024519982A (es)
KR (1) KR20240021824A (es)
CN (1) CN117750980A (es)
AU (1) AU2022283315A1 (es)
CA (1) CA3218663A1 (es)
IL (1) IL308508A (es)
MX (1) MX2023013619A (es)
TW (1) TW202313121A (es)
WO (1) WO2022247708A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
CN105267982A (zh) * 2015-11-20 2016-01-27 暨南大学 一种rhHER2抗体与MMAE偶联物及其制备方法与应用
SG10201912173RA (en) * 2016-10-07 2020-02-27 Daiichi Sankyo Co Ltd Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
WO2020042941A1 (zh) * 2018-08-29 2020-03-05 荣昌生物制药烟台有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途

Also Published As

Publication number Publication date
CN117750980A (zh) 2024-03-22
IL308508A (en) 2024-01-01
EP4346908A1 (en) 2024-04-10
AU2022283315A1 (en) 2023-11-16
JP2024519982A (ja) 2024-05-21
CA3218663A1 (en) 2022-12-01
TW202313121A (zh) 2023-04-01
US20240207424A1 (en) 2024-06-27
WO2022247708A1 (en) 2022-12-01
KR20240021824A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
EP4295899A3 (en) Apparatus for fat and cellulite reduction using rf energy in combination with magnetic muscle thermostimulation (ems)
WO2004112890A3 (en) Method for intraoperative radiation treatment of breast cancer
Babovic Complete breast reconstruction with autologous fat graft–a case report
ZA202209988B (en) In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material
Hwang et al. Clinical effectiveness of complex decongestive physiotherapy for malignant lymphedema: a pilot study
MX2023013619A (es) Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2.
CN211024852U (zh) 一种肿瘤放疗床
Gameeva et al. Comprehensive rehabilitation of cancer patients: a review
Pyo et al. Vaccum-assisted closure therapy in split-thickness skin graft on the wound on the contours of the body
de la Peña et al. Subfascial gluteal augmentation
CN217938472U (zh) 主动脉瘤和主动脉夹层治疗用覆膜与裸部混合支架
CN205867321U (zh) 一种用于乳腺放疗的体位固定装置
Sasaki Tissue expansion
Hong et al. The role of the pars recta and pars oblique of cricothyroid muscle in speech production
RU2705445C1 (ru) Способ повышения защитных сил организма при лечении осложнений и сопутствующей патологии у онкологических больных при различных локализациях опухолей на этапах комбинированного лечения
Vasconez et al. Use of the TRAM and latissimus dorsi flaps in autogenous breast reconstruction
RU2341215C1 (ru) Способ реконструкции верхней челюсти
Aksam et al. A practical way for nipple-areola complex reshaping in circumareolar reduction of gynecomastia
MX2023009376A (es) Uso de conjugado de anticuerpo-farmaco dirigido a her2 en el tratamiento de cancer de mama especifico.
Sobolevsky et al. RECONSTRUCTIVE AND PLASTIC SURGERY FOR BREAST CANCER
CN111110285A (zh) 一种原生双平面丰胸方法
Deleyiannis et al. Reconstruction of the marginal mandibulectomy defect: an update
Huang et al. Chin projection creation in patients with facial and cervical burn scar contracture
Cuccia et al. Hybrid mastopexy: improving outcomes on implant-based augmentation mastopexy with fat
Hassan et al. Surgical treatment of vitiligo